ARUP's Laboratory Test Directory
| 0099230: Interleukin 2 by ELISA |
| Test Mnemonic: IL2 | |
|
#ExistMethodology>
Methodology: Enzyme-Linked Immunosorbent Assay
*ExistMethodology> #ExistPerformed> Performed: Second and fourth Tue *ExistPerformed> #ExistReported> Reported: 1-21 days *ExistReported> |
| Specimen Required: | |
|
#ExistCollect>
Collect: One 6 mL SST, one 3 mL lavender (EDTA) or pink (K2EDTA), one 3 mL green (sodium or lithium heparin), or joint fluid. Cell-free culture supernatants are also acceptable.
*ExistCollect> #ExistTransport> Transport: 1 mL serum, plasma, joint fluid, or cell-free culture supernatant, frozen. (Min: 0.5 mL) Submit specimen in an ARUP Standard Transport Tube. *ExistTransport> #ExistPedCollectTransport> Pediatric Collection/Transport: 0.3 mL serum, plasma, joint fluid, or cell-free culture supernatant, frozen. *ExistPedCollectTransport> #ExistRemarks> Remarks: CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered. Separate serum, plasma, or fluid within 30 minutes from cells and freeze. Avoid freeze/thaw cycles. *ExistRemarks> #ExistConditions> Unacceptable Conditions: Severely hemolyzed, contaminated, heat-inactivated, refrigerated, or lipemic specimens. *ExistConditions> #ExistStability> Stability: After separation from cells: Ambient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 year *ExistStability> |
|
| Reference Interval: |
| #ExistRefRange> < 31.2 pg/mL *ExistRefRange> |
| Interpretive Data: | |
|
#ExistInterpData>
Please refer to Statement D in the Compliance Statements section in the front of the Laboratory Test Directory. *ExistInterpData> |
| Note: | |
|
Interleukin 2 (IL-2) is a glycoprotein produced by activated T-cells that has a variety of immunologic functions, the most notable being the ability to promote the proliferation and maturation of activated T-cells. It has been known by various names, including T-Cell Growth Factor (TCGF), Thymocyte Stimulation Factor (TSF), Thymocyte Mitogenesis Factor (TMF), T-Cell Replacing Factor (TRF), and Killer Helper Factor (KHF). Decreased production of this cytokine has been associated with the following disease states: systemic lupus erythematosus (SLE), Hodgkin disease, lepromatous leprosy, and AIDS. The ability of IL-2 to stimulate natural killer cells and enhance their cytotoxicity has led to the combined usage of IL-2 and LAK cells for the treatment of certain cancers. |
| CPT Code(s): | |
| 83520 |